New Phase III Study Shows Strong Efficacy and Favorable Safety Profile With Single-Agent MabCampath(R) (alemtuzumab) for Patients with Previously Untreated B-CLL
Leeds, England (ots/PRNewswire) - - Significant Response Rates and Manageable Side Effects Also Exhibited In Poor-Prognosis and Difficult-to-Treat Patients According to interim data from a new international Phase III study called CAM 307, previously untreated patients with progressive B-cell chronic ...
plus